(Q57244448)

https://api.crossref.org/works/10.1517%2F14728210902771334

The clinical spectrum of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Assessing the impact of psoriasis and the relevance of qualitative research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Psoriasis and metabolic disease: epidemiology and pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Incidence and risk factors for psoriasis in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Epidemiology of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

The genetic basis of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Smoking and the risk of psoriasis in women: Nurses' Health Study II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Quality of life in patients with psoriasis and psoriasis arthritis with a special focus on stigmatization experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Impact of psoriasis on health-related quality of life decreases over time: an 11-year prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Study design and preliminary results from the pilot phase of the PraKtis study: self-reported diagnoses of selected skin diseases in a representative sample of the Italian population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Current and future management of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Incorporating patient preferences into randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Topical preparations for the treatment of psoriasis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Psoralen and ultraviolet a light therapy for psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Controlled study of excimer and pulsed dye lasers in the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Central role of mitochondria and p53 in PUVA-induced apoptosis in human keratinocytes cell line NCTC-2544.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Trioxsalen bath PUVA did not increase the risk of squamous cell skin carcinoma and cutaneous malignant melanoma in a joint analysis of 944 Swedish and Finnish patients with psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Ciclosporin in psoriasis clinical practice: an international consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Dimethylfumarate is a potent inducer of apoptosis in human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Treatment of psoriasis with fumaric acid esters (Fumaderm).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Relapse, rebound, and psoriasis adverse events: an advisory group report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Current concepts and review of alefacept in the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Current concepts and review of efalizumab in the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

The treatment of psoriasis and psoriatic arthritis with etanercept: practical considerations on monotherapy, combination therapy, and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Psoriasis and its treatment with infliximab-mediated tumor necrosis factor alpha blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Randomized Clinical Trials for Psoriasis 1977–2000: The EDEN Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Pathogenesis and therapy of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Innate and adaptive immunity and the pathophysiology of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Pathogenesis and clinical features of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Identification and isolation of candidate human keratinocyte stem cells based on cell surface phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Psoriasis: the epidermal component

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Oral R115866 in the treatment of moderate to severe plaque-type psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

The anti-inflammatory effect of A3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

The biology of p38 kinase: a central role in inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Emerging Flt3 kinase inhibitors in the treatment of leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Novel immunosuppression: R348, a JAK3- and Syk-inhibitor attenuates acute cardiac allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

The PKC inhibitor AEB071 may be a therapeutic option for psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: A prospective clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334

Polymorphisms in Folate, Pyrimidine, and Purine Metabolism Are Associated with Efficacy and Toxicity of Methotrexate in Psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902771334